- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT00155727
Comparison of Laparoscopic Colectomy Versus Open Colectomy for Colorectal Cancer: … A Prospective Randomized Trial
Comparison of Treatment Outcome for Laparoscopic Colectomy Versus Traditional Open Colectomy for the Treatment of Colorectal Cancer: … A Prospective Randomized Clinical Trial
The laparoscopic colectomy has been enthusiastically used by many colorectal surgeons in Taiwan, Japan, Europe, and USA, for around 10 years. Further clarification of the controversies cited above will be based on the evidence-based medicine, i.e., the randomized, well-controlled, prospective clinical trials. Actually, a handful of randomized prospective data regarding the laparoscopic colectomy has been appeared in USA and Europe. However, we still do not have this kind of data in Taiwan, and therefore this study is important and mandatory.
In this project, we assumed that a difference in cancer-related survival of less then 15% between treatments indicates an equivalent efficacy. Assuming a 70% 5-year, cancer-related survival of stage II and III colorectal cancer patients in the open colectomy group, a minimum of 100 patients per group was required to showed that both surgical techniques were equivalent with an α-level of 0.20 and a β error of 0.05. Only patients with stage II and III disease undergoing curative resection will be enrolled onto this study. The patients will be randomly allocated to either treatment group by block randomization method. Postoperatively, the patients will be prospectively evaluated regarding the following parameters including operative stress, such as erythrocyte sedimentation rate, serum interleukin-6, WBC counts and classification, CD-4 to CD-8 ratio, postoperative life quality, such as wound size, degree of pain, time to have flatus passage and feeding, time to resume daily activity and work, and the oncological outcomes, such as recurrence patterns of tumor, and 5-year patient survival. The evaluation of above-mentioned parameters will be single-blindly done by our research assistant, who has no idea of both surgical techniques. We hope this study will promote the level of surgical research in Taiwan.
Studieoversikt
Status
Forhold
Detaljert beskrivelse
The appropriateness of laparoscopic surgery for the resection of colorectal cancer has been the focus of controversy. The pros insist that besides the smaller wound size, laparoscopic colectomy should induce lesser perioperative stress, which was evidenced by the less pain, quicker flatus passage, early feeding, and more rapid to resume daily activity and work. Moreover, since the laparoscopic colectomy induces lesser immunosuppression, this may be potentially positive for the treatment of colorectal cancer patients. However, the cons insist that first of all, when the summation of 4 or 5 ports, and incisional wound to retrieve specimen in laparoscopic colectomy were considered, the total wound size in laparoscopic colectomy is basically similar to that of the open colectomy. Secondly, since the laparoscopic surgeons advocated that the extent of intra-abdominal dissection was the same between laparoscopic and open colectomy, it seems illogical to speculate that laparoscopic procedure is less invasive for the colorectal cancer patients than the open procedure. Moreover, in regard of the short-term improvement of life quality (based on the evaluation of parameters including less painful, quicker to have flatus passage, feeding, to resume daily activity, to return to work, etc.), there is no denying that these potential benefits are at the sacrifice of spending more money, and therefore, it is still unknown if laparoscopic colectomy is cost-effective. Thirdly and most important of all, laparoscopic colectomy is a more difficult for most surgeons, and therefore the learning curve is more difficult to overcome. Moreover, many surgeons concerned if pneumoperitoneum during the laparoscopic procedure will reinforce the intraperitoneal spread of colorectal cancer. Based on above-mentioned reasons, many colorectal surgeons hesisted between the lines of safety and efficacy of laparoscopic colectomy.
However, apparently, the laparoscopic colectomy has been enthusiastically used by many colorectal surgeons in Taiwan, Japan, Europe, and USA, for around 10 years. Further clarification of the controversies cited above will be based on the evidence-based medicine, i.e., the randomized, well-controlled, prospective clinical trials. Actually, a handful of randomized prospective data regarding the laparoscopic colectomy has been appeared in USA and Europe. However, we still do not have this kind of data in Taiwan, and therefore this study is important and mandatory.
In this project, we assumed that a difference in cancer-related survival of less then 15% between treatments indicates an equivalent efficacy. Assuming a 70% 5-year, cancer-related survival of stage II and III colorectal cancer patients in the open colectomy group, a minimum of 100 patients per group was required to showed that both surgical techniques were equivalent with an α-level of 0.20 and a β error of 0.05. Only patients with stage II and III disease undergoing curative resection will be enrolled onto this study. The patients will be randomly allocated to either treatment group by block randomization method. Postoperatively, the patients will be prospectively evaluated regarding the following parameters including operative stress, such as erythrocyte sedimentation rate, serum interleukin-6, WBC counts and classification, CD-4 to CD-8 ratio, postoperative life quality, such as wound size, degree of pain, time to have flatus passage and feeding, time to resume daily activity and work, and the oncological outcomes, such as recurrence patterns of tumor, and 5-year patient survival. The evaluation of above-mentioned parameters will be single-blindly done by our research assistant, who has no idea of both surgical techniques. We hope this study will promote the level of surgical research in Taiwan.
Studietype
Registrering
Kontakter og plasseringer
Studiesteder
-
-
-
Taipei, Taiwan, 100
- Rekruttering
- Department of Surgery, National Taiwan University Hospital, No.7, Chung-Shan South Road, Taipei, TAIWAN, R.O.C.
-
Ta kontakt med:
- Jin-Tung Liang, M.D., Ph.D.
- Telefonnummer: 886-2-23562068
- E-post: jintung@ha.mc.ntu.edu.tw
-
Hovedetterforsker:
- Jin-Tung Liang, M.D., Ph.D.
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- All consecutive patients admitted to our unit since January 2000 with adenocarcinoma of the colon and rectum will be assessed.
Exclusion Criteria:
- Cancer with distant metastasis, adjacent organ invasion, intestinal obstruction, past colonic surgery, and no consent to participate in the study.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Tidsperspektiver: Potensielle
Samarbeidspartnere og etterforskere
Studierekorddatoer
Studer hoveddatoer
Studiestart
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- 9100017028
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Tykktarmskreft
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Aktiv, ikke rekrutterendeMetastatisk kolorektalt karsinom | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8Forente stater
-
Academic and Community Cancer Research UnitedNational Cancer Institute (NCI)FullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Kolorektalt adenokarsinom | RAS Wild TypeForente stater
-
Ning JinAktiv, ikke rekrutterendeMetastatisk kolorektalt karsinom | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8Forente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)FullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatisk karsinom i leveren | Resektabel masseForente stater
-
University of California, San FranciscoMerck Sharp & Dohme LLCFullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Mikrosatellitt stabil | Trinn III tykktarmskreft AJCC v7 | Trinn IIIB tykktarmskreft AJCC v7 | Stage IIIC tykktarmskreft AJCC v7 | Mismatch Repair Protein dyktigForente stater
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)FullførtTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Tilbakevendende kolorektalt karsinom | Metastatisk karsinom i leverenForente stater
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI); Genentech, Inc.Aktiv, ikke rekrutterendeTrinn IV tykktarmskreft AJCC v7 | Stage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Metastatisk malignt fast neoplasma | Ikke-opererbar fast neoplasma | BRAF NP_004324.2:p.V600X | KRAS wt AllelForente stater
-
M.D. Anderson Cancer CenterRekrutteringMetastatisk malign neoplasma i leveren | Metastatisk kolorektalt karsinom | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8 | Resektabelt kolorektalt karsinomForente stater
-
Chloe Atreya, MD, PhDMerck Sharp & Dohme LLC; MedPacto, Inc.RekrutteringMetastatisk malign neoplasma i leveren | Trinn IV tykktarmskreft AJCC v8 | Stage IVA tykktarmskreft AJCC v8 | Stage IVB tykktarmskreft AJCC v8 | Stage IVC Colorectal Cancer AJCC v8Forente stater
-
National Cancer Institute (NCI)Aktiv, ikke rekrutterendeStage IVA kolorektal kreft AJCC v7 | Stage IVB Colorectal Cancer AJCC v7 | Tilbakevendende kolorektalt karsinom | Trinn IIIA tykktarmskreft AJCC v7 | Trinn IIIB tykktarmskreft AJCC v7 | Stage IIIC tykktarmskreft AJCC v7 | Solid neoplasmaForente stater, Canada